May 30, 2020 9:44am
A scorecard of 32 (added PSTI) earnings "confessions", 1 restatement and 1 acquisition of 35 covered companies
Added Mesoblast (MESO) and Precision (PGEN)
The current LPS (loss per share) or net income, cash positions i.e. "runways" is a reflection of this universe's investing "status"
|
COMPANY |
SYMBOL | NET INCOME | Q1/20 LOSS | Q1/20 LPS | Q1/20 CASH | RUNWAY |
|---|---|---|---|---|---|---|
| Aduro Biotech, Inc. | ADRO | -$7.6 M | -$0.09 | $205.9 M | early 2023 | |
| Alnylam Pharmaceuticals | ALNY | -$182 M | -$1.62 | $1.37 Billion | 2025 | |
| Applied Genetic Technologies | AGTC |
-$11.2 M (Q3) |
-$0.50 | $84.5 M | 2021 | |
| Athersys, Inc. | ATHX | -$15.6 M | -$0.10 |
$32.7 M EOY +$57.6 M offering |
2022 | |
| Adverum Biotechnologies, Inc. | ADVM | -$22.9 M | -$0.31 | $297. 1 M | 2022 | |
| AxoGen, Inc. | AXGN | -$8.19 M | -$0.21 | $89 M | 2021 | |
| Bellicum Pharmaceuticals | BLCM |
$17.57 M or +$1.09 |
$75.5 M | 2H/2021 | ||
| BioLife Solutions, Inc. | BLFS |
+$22.3 M or +$0.87 |
$6.4 M + $12.2 M revenue $20 M from Casdin Capital ++ |
2022 | ||
| Biostage, Inc. | BSTG | -$2 M | -$0.24 | $800 K | Q3/2020 | |
| bluebird bio | BLUE | -$202.6 M | -$3.64 | $1.02 Billion | 2022 | |
| Brainstorm Cell Therapeutics | BCLI | -$8.1 M | -$0.31 |
$14.5 M + $50 ATM |
2021 | |
| Caladrius Biosciences. | CLBS | -$4 M | -$0.38 |
$34 M from RDO + sales of NOLs |
Q2/2021 |
|
| Cellectis SA | CLLS |
+$20 M +$0.47 |
$351 M | 2022 | ||
| CRISPR Therapeutics | CRSP | -$69.7 M | -$1.15 | $889.7 M | 2022 | |
| Editas Medicine | EDIT | -$37.7 M | -$0.69 | $415 M | Q1/2021 | |
| Fate Therapeutics | FATE | -$33.5 M | -$0.44 |
$219 M $100 M Janssen/J&J collab |
2022 | |
| Global Blood Therapeutics | GBT | -$73 M | -$1.20 | $615 M | 2022 | |
| Homology Medicine | FIXX | -$35.3 M | -$0.78 | $234.9 M | Q4/2021 | |
| Intellia Therapeutics | NTLA | -$31.8 M | -$0.63 | $250.3 M | Q1/2021 | |
|
Precigen formerly Intrexon Corporation |
PGEN | -$55.99 M | -$0.35 | $149.1 M | Q3/2021 | |
| Ionis Pharmaceuticals | IONS |
+$59 M +$0.35 |
$2.4 M | 2025 | ||
| Mesoblast Limited | MESO | -$15.2 M (Q3) | -$2.84 |
$60.1 M + $90 M raise |
Q3/2021 | |
| MiMedx Group, Inc |
OTC PINK: MDXG |
Restating | ||||
| Pluristem Therapeutics, Inc. | PSTI | -$21 M | -$1.28 |
$6.7 M $US$64.93 M + $15 M raise |
2022 | |
| ReNeuron Group PLC | RENE.L | |||||
| Regenxbio | RGNX | -$40 M | -$1.08 | $356.6 M | 2022 | |
| Sage Therapeutics | SAGE | -$126.& M | -$2.44 | $900 M | 2022 | |
| Sangamo Biosciences, Inc. | SGMO | -$42.9 M | -$0.37 |
$384 M+ $350 M BIIB collab |
2023 | |
| Solid Biosciences | SLDB | -$26.94 M | -$0.56 | $53.8 M | Q1/2021 | |
| Stemline Therapeutics, Inc. | STML |
Acquired by Menarini, an Italian pharma |
||||
| Ultragenyx | RARE | -$119 M | -$2.05 | $705 M | 2022 | |
| uniQure N.V. | QURE | -$28 M | -$0.63 | $342 M | 2022 | |
| Verastem, Inc. | VSTM | -$38 M | -$0.35 |
$170 .7 M with PP of $93.8 M |
2022 | |
| Vericel Corporation | VCEL | -$4.7 M | -$0.10 | $83.3 M | 2022 | |
| Voyager Therapeutics | VYGR | -$24.3 M | -$0.66 | $250.9 M | 2022 |
